These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 30382885)

  • 21. Transition from androgenic to neurosteroidal action of 5α-androstane-3α, 17β-diol through the type A γ-aminobutyric acid receptor in prostate cancer progression.
    Xia D; Lai DV; Wu W; Webb ZD; Yang Q; Zhao L; Yu Z; Thorpe JE; Disch BC; Ihnat MA; Jayaraman M; Dhanasekaran DN; Stratton KL; Cookson MS; Fung KM; Lin HK
    J Steroid Biochem Mol Biol; 2018 Apr; 178():89-98. PubMed ID: 29155210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progesterone receptor in the prostate: A potential suppressor for benign prostatic hyperplasia and prostate cancer.
    Chen R; Yu Y; Dong X
    J Steroid Biochem Mol Biol; 2017 Feb; 166():91-96. PubMed ID: 27125450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Construction and analysis of protein-protein interaction networks based on proteomics data of prostate cancer.
    Chen C; Shen H; Zhang LG; Liu J; Cao XG; Yao AL; Kang SS; Gao WX; Han H; Cao FH; Li ZG
    Int J Mol Med; 2016 Jun; 37(6):1576-86. PubMed ID: 27121963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
    Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
    Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
    Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
    Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy.
    Zeng J; Liu W; Fan YZ; He DL; Li L
    Theranostics; 2018; 8(1):109-123. PubMed ID: 29290796
    [No Abstract]   [Full Text] [Related]  

  • 27. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
    Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
    Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Molecular targeting drug of kinase inhibitors for castration resistant prostate cancer].
    Kosaka T; Oya M
    Nihon Rinsho; 2014 Dec; 72(12):2186-92. PubMed ID: 25518356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteomic Comparison and MRM-Based Comparative Analysis of Metabolites Reveal Metabolic Shift in Human Prostate Cancer Cell Lines.
    Shu Q; Cai T; Chen X; Zhu HH; Xue P; Zhu N; Xie Z; Wei S; Zhang Q; Niu L; Gao WQ; Yang F
    J Proteome Res; 2015 Aug; 14(8):3390-402. PubMed ID: 26147661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer.
    Audet-Walsh É; Dufour CR; Yee T; Zouanat FZ; Yan M; Kalloghlian G; Vernier M; Caron M; Bourque G; Scarlata E; Hamel L; Brimo F; Aprikian AG; Lapointe J; Chevalier S; Giguère V
    Genes Dev; 2017 Jun; 31(12):1228-1242. PubMed ID: 28724614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reconfiguring the AR-TIF2 Protein-Protein Interaction HCS Assay in Prostate Cancer Cells and Characterizing the Hits from a LOPAC Screen.
    Fancher AT; Hua Y; Camarco DP; Close DA; Strock CJ; Johnston PA
    Assay Drug Dev Technol; 2016 Oct; 14(8):453-477. PubMed ID: 27606620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complex impacts of PI3K/AKT inhibitors to androgen receptor gene expression in prostate cancer cells.
    Liu L; Dong X
    PLoS One; 2014; 9(10):e108780. PubMed ID: 25360799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Harnessing the 14-3-3 protein-protein interaction network.
    Pitasse-Santos P; Hewitt-Richards I; Abeywickrama Wijewardana Sooriyaarachchi MD; Doveston RG
    Curr Opin Struct Biol; 2024 Jun; 86():102822. PubMed ID: 38685162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Computer-Aided Discovery of Small Molecules Targeting the RNA Splicing Activity of hnRNP A1 in Castration-Resistant Prostate Cancer.
    Carabet LA; Leblanc E; Lallous N; Morin H; Ghaidi F; Lee J; Rennie PS; Cherkasov A
    Molecules; 2019 Feb; 24(4):. PubMed ID: 30791548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of novel androgen receptor target genes in prostate cancer.
    Jariwala U; Prescott J; Jia L; Barski A; Pregizer S; Cogan JP; Arasheben A; Tilley WD; Scher HI; Gerald WL; Buchanan G; Coetzee GA; Frenkel B
    Mol Cancer; 2007 Jun; 6():39. PubMed ID: 17553165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
    Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
    Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
    Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
    Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of Core Genes and Potential Drugs for Castration-Resistant Prostate Cancer Based on Bioinformatics Analysis.
    Liang X; Hu K; Li D; Wang Y; Liu M; Wang X; Zhu W; Wang X; Yang Z; Lu J
    DNA Cell Biol; 2020 May; 39(5):836-847. PubMed ID: 32101033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Computational techniques are valuable tools for the discovery of protein-protein interaction inhibitors: the 14-3-3σ case.
    Corradi V; Mancini M; Santucci MA; Carlomagno T; Sanfelice D; Mori M; Vignaroli G; Falchi F; Manetti F; Radi M; Botta M
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6867-71. PubMed ID: 21962576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Linking γ-aminobutyric acid A receptor to epidermal growth factor receptor pathways activation in human prostate cancer.
    Wu W; Yang Q; Fung KM; Humphreys MR; Brame LS; Cao A; Fang YT; Shih PT; Kropp BP; Lin HK
    Mol Cell Endocrinol; 2014 Mar; 383(1-2):69-79. PubMed ID: 24296312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.